HS Beyond the Lesion — What the Skin Is Not Telling You

The Lesion Is Not the Disease

When a patient with HS first seeks medical attention, what they present — and what the physician observes — is a lesion. A painful lump in the underarm. A draining abscess in the groin. A cluster of nodules beneath the breast. These are visible, measurable, and clearly in need of attention. They become the focus of evaluation and, consequently, the target of treatment.

This is understandable. The lesion is what hurts. It is what interrupts daily life. It is what generates the urgent need for relief. But treating the lesion as the disease — rather than as evidence of the disease — is the reason so many people with HS find themselves in a cycle of temporary improvement followed by reliable relapse. The lesion resolves. The process generating it does not.

HS is not a skin condition that produces systemic consequences. It is a systemic condition that expresses itself through the skin. This distinction is not semantic. It determines whether treatment is designed to address what is presenting or what is causing the presentation. Every intervention that targets only the lesion leaves the internal architecture of the disease intact — and that architecture continues generating new lesions as reliably as it generated the previous ones.

What the Lesion Is Actually Telling You

A lesion, understood correctly, is a readout — a visible signal that a set of internal processes have reached a threshold of expression at a particular site. The specific site matters: HS lesions are not randomly distributed. They appear consistently in areas with a particular combination of anatomical features — dense follicular populations, proximity to apocrine glands, susceptibility to friction, and limited lymphatic drainage. Underarms. Groin. Beneath the breast. Gluteal folds. These are not arbitrary locations. They are areas where a specific combination of factors makes follicular occlusion likely when the internal environment supports it.

But the location is the site of expression, not the site of origin. What determines whether a nodule forms in the underarm on a given day is not the condition of the underarm — it is the state of the internal environment that is generating the inflammatory pressure that the underarm is susceptible to expressing. Reduce the inflammatory pressure, correct the hormonal environment, restore the gut's regulatory function, and the underarm — structurally unchanged — stops producing lesions. Because what was driving them is no longer doing so.

The Internal Drivers Beneath Every Flare

Three interconnected systems drive HS beneath the surface, operating continuously regardless of whether a lesion is currently active.

Gut dysfunction is the most foundational and most frequently overlooked. A compromised gut lining allows incompletely metabolised compounds to enter systemic circulation, creating a persistent, low-grade inflammatory signal that keeps the immune system in a state of sustained activation. This is the background inflammatory pressure that HS lesions express. It does not announce itself dramatically — it simply maintains the systemic state that makes follicular occlusion an inflammatory event rather than a minor, self-resolving one. Patients often do not associate their gut health with their skin — but the gut-skin connection is mechanistically well-established and directly relevant to understanding why HS behaves the way it does.

Hormonal imbalance — most commonly androgen excess and its interaction with insulin resistance — creates the follicular environment in which occlusion is more likely and the inflammatory response more severe. Androgens regulate sebum production and influence follicular keratinisation; when androgen activity is elevated, the follicular environment becomes more prone to blockage. This is why HS is significantly more common in women with PCOS, why flares frequently correlate with menstrual cycle phases, and why metabolic factors like insulin resistance directly influence disease severity. The hormonal driver is not a separate issue from the skin presentation — it is a direct upstream cause of it.

Immune dysregulation determines how the body responds when follicular occlusion occurs. In HS, this response is characteristically disproportionate — a minor follicular blockage triggers an inflammatory cascade that would, in a well-regulated immune system, be reserved for genuine infection. The result is the depth, severity, and tissue-destructive nature of HS lesions compared to ordinary folliculitis. The immune dysregulation does not create the lesion, but it determines its character: whether it resolves quickly and completely, or deepens, spreads, and leaves structural consequences behind.

The Gap Between the Lesion and the Disease

Between what is visible on the skin and what is driving it, there is a significant gap — and most treatment approaches operate only on the visible side of that gap. Antibiotics reduce the bacterial component of the inflammatory lesion. Steroids blunt the inflammatory response. Surgery removes the structural consequence of repeated inflammation. These are not ineffective interventions — they address real aspects of the clinical picture. But none of them reach the internal environment that is generating the picture. And so, when the intervention is withdrawn, the picture reconstitutes itself.

This is what patients experience as the treatment cycle: a course of antibiotics, improvement, relapse. A steroid injection, resolution, recurrence within weeks. A surgical procedure, healing, new lesions in adjacent areas. Each of these outcomes makes complete sense if the internal drivers are understood. The treatment cleared the current expression of those drivers. The drivers themselves remained active, continued generating the same internal environment, and that environment produced the same result — in the same location, or the next susceptible one.

Why Recurrence Is Predictable, Not Random

Many patients describe HS recurrence as unpredictable — appearing without apparent trigger, in new locations, at unexpected times. But when the internal drivers are understood, recurrence is actually quite predictable. It reflects the fact that the internal environment generating HS has not changed. The gut is still compromised. The hormonal balance is still disrupted. The immune regulation is still dysregulated. In this environment, lesions will reliably continue to form — because the conditions that produce them remain intact.

What feels unpredictable is which specific lesion will form next, and exactly when. But the fact that lesions will continue to form — absent internal correction — is entirely predictable. Recurrence is not bad luck. It is the expected output of an uncorrected system.

What Exists Beyond the Lesion — The Systemic Picture

In patients who have lived with HS for years, the systemic picture is often more complex than the skin presentation alone would suggest. Chronic gut inflammation alters the intestinal microbiome in ways that amplify the inflammatory signal and impair the regulatory immune responses that would otherwise limit it. Sustained androgen excess and insulin resistance compound each other over time — insulin resistance worsens hormonal regulation, and hormonal imbalance impairs insulin sensitivity. Chronic pain from HS disrupts sleep; disrupted sleep elevates cortisol; elevated cortisol worsens both gut function and immune regulation; both of these worsen HS.

These are not separate problems that happen to coexist with HS. They are expressions of the same internal imbalance that is driving HS — and they amplify each other in ways that progressively entrench the disease. What began as a relatively contained systemic disruption becomes, over years, a more deeply established state that is harder to correct precisely because its various components have been reinforcing each other for so long.

The Lymphatic Dimension

There is a further dimension that is rarely discussed in standard HS management: the role of lymphatic function. The areas where HS most commonly appears — underarms, groin, beneath the breast — are also areas where lymphatic drainage is highest and, in chronic inflammatory states, most likely to become congested. Lymphatic stagnation in these areas means that inflammatory debris, cellular waste products, and accumulated toxins are less efficiently cleared from the local tissue environment. This creates a localised condition in which the concentration of inflammatory mediators remains elevated even between flares — maintaining a tissue environment that is perpetually primed for the next episode.

Restoring lymphatic function in these areas is not a primary treatment for HS, but it is a meaningful component of reducing the local inflammatory burden that contributes to recurrence frequency and severity. It is also a component of treatment that is almost entirely absent from conventional HS management — because conventional management is oriented toward the lesion, not toward the internal environment in which the lesion forms.

What Addressing the Disease — Not the Lesion — Actually Requires

A treatment approach that reaches beyond the lesion requires a different starting point. Instead of beginning with what is visible and working backward to find something to suppress it, it begins with a structured assessment of which internal drivers are active — and in what combination — and works forward to a programme of correction directed at those drivers.

This is not a simpler approach than lesion management. It requires a more complete picture of the patient: their gut function, their hormonal profile, their metabolic state, their disease stage, their history of treatment and its effects. It requires phased implementation — because correcting a system that has been disrupted for years cannot happen simultaneously at all levels. And it requires time — because internal correction is a process, not an event.

But it is the only approach that addresses what is actually generating the disease. Every other approach — however effective it may be at managing the current presentation — leaves the engine running. And an engine that is left running continues to produce the same output.

The Practical Implication

For patients who have been managing HS for years with approaches directed at the lesion — antibiotics, topicals, injections, surgery — understanding what exists beyond the lesion is the first step toward a different outcome. Not because the previous approaches were wrong, but because they were incomplete. They addressed the expression of the disease, not its drivers. And as long as the drivers remain uncorrected, the expression will continue.

The internal architecture of HS is correctable. Gut function can be restored. Hormonal balance can be re-established. Immune regulation can be improved. These are not aspirational claims — they are the logical targets of treatment once the disease is understood as systemic rather than dermatological. Reaching those targets requires a structured, personalised approach. But they are reachable. And when they are reached, the lesions — which were never the disease itself, only its expression — stop appearing with the same reliability they once did.